


Institutional Pharmacy Practice Research



Chris Fausel, PharmD, BCPS, BCOP

Clinical Director

Oncology Pharmacy Services

Indiana University Cancer Center

Indianapolis, Indiana

Disclosure

- Chris Fausel, PharmD, BCPS, BCOP has received consulting fees from Abraxis Oncology, Pfizer, and Amgen

Presentation Outline

- Research models in institutional practice
- Strengths and weaknesses in institutional practice research
- Resource allocation
- Funding opportunities

Traditional Institutional Pharmacy Research

- Drug utilization projects
- Clinical pathway development
- Adverse drug reaction (ADR) reporting
- Performance improvement

Drug Utilization Review

- High-risk drugs
 - Antineoplastics
 - Anticoagulants
 - Antibiotics
- High-cost drugs
- Supportive care

Clinical Pathway Development

- Inpatient
 - Disease-related treatments
 - Supportive care
- Outpatient
 - Chemotherapy treatment algorithms
 - Thresholds for enacting supportive care measures
 - Hypersensitivity protocols

ADR Reporting

- Continuous monitoring of high-risk drugs
- Vigilance for new agents with undefined toxicity profile
- Trending for changes in reporting for formulary class substitution
- Expected events
 - *Clostridium difficile* (C-diff) diarrhea

Performance Improvement

- Adherence to institutional practice guidelines
- Chemotherapy ordering, compounding, dispensing, and administration
- Antibiotic/antifungal use
- Cerebrospinal fluid studies, intravenous immune globulin, monoclonal antibodies, etc.

Drug Studies

- Drug development
- Intravenous (IV) compatibility studies
- Informatics
- Pharmacokinetics/Pharmacodynamics
- Pharmacogenomics

Drug Studies

- Your own novel idea
- Contribute to a physician colleague's protocol
 - Drug monograph
 - Supportive care section
 - Dose modifications for toxicity
 - Informed consent

Cooperative Groups

- Pharmacy committees
 - Drug monographs
 - Informed consent toxicity listings
 - Protocol review
- Disease-specific committees

Research Oversight

- Cancer center scientific review committee
- Institutional review board (IRB)
- Central IRBs
- Data safety monitoring boards
- Institutional auditing

Personnel

- YOU!
- Pharmacy residents
- Pharmacy students
- Clinical research office
- Volunteers
- Physician collaboration

Funding Opportunities

- Industry funds
- Institutional start-up funds
- Federal grants
- Grants through professional societies
 - American Society of Health-System Pharmacists (ASHP)
 - American Society of Clinical Oncologists (ASCO)
 - Leukemia/Lymphoma Society

Disadvantages of Institutional Research

- Funding not always readily available
- Health system may not support pharmacist-led research
- Lack of protected research time for pharmacists
- Cumbersome research review process

Advantages for Institutional Research

- Multiple collaborators on-site
- Availability of data (maybe)
- Biostatistical support (maybe)
- Collaboration with schools of pharmacy
- Potential for multidisciplinary projects (with nursing)